Hepatitis C in Patients with Multi Blood Transfusion

Document Type : Original Article(s)

Authors

1 Researcher, Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

2 Specialist in Community Medicine, Disease Control Unit, Isfahan Province Health Center, Isfahan University of Medical Sciences, Isfahan, Iran.

3 Associate Professor, Department of Infectious Diseases, School of Medicine and Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

4 Associate Professor, Department of Gastroenterology, School of Medicine and Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

Background: Frequent transfusion of blood and blood products to patients with thalassemia major and hemophilia and under hemodialysis patients may cause infections such as hepatitis infection in them. This study aimed to determine the prevalence of hepatitis C and associated risk factors in these patients in Isfahan, the second big province in Iran.Methods: In a descriptive study, all the patients with hemophilia and thalassemia and under hemodialysis in Isfahan province were enrolled. A questionnaire, including demographic and risk factors of hepatitis C was completed through a structured interview with closed questions by a trained interviewer for each patient and HCV-Ab test results were extracted from patient records.Finding: In this study, 60of 570 patients with thalassemia major (10.5%), 232 of 350 patients with hemophilia A and B (66%) and 17 of 800 under hemodialysis patients (2.1%) were positive for hepatitis C. Based on Multivariate Logistic Regression model, no independent risk factor was found.Conclusion: Prevalence of hepatitis C in patients with recurrent blood transfusion in Isfahan is high. Since no independent risk factor for hepatitis C disease was found in these three groups, it can be concluded that multitransfusion is the only predictor for hepatitis C.  

Keywords


  1. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003; 289(8): 959-62.
  2. Tong MJ, el Farra NS, Reikes AR, Co RL. Clini- cal outcomes after transfusion-associated hepati- tis C. N Engl J Med 1995; 332(22): 1463-6.
  3. Costello M, Yungbluth M. Viral infections. In: Henry JB, Davey FR, Herman CJ, McPherson RA, Pincus MR, Threatte GA, et al., editors. Clinical Diagnosis and Management by Labora- tory Methods. Philadelphia : Saunders, 2001: 1064-6.
  4. Rezvan H, Abolghassemi H, Kafiabad SA. Transfusion-transmitted infections among multi- transfused patients in Iran: a review. Transfus Med 2007; 17(6): 425-33.
  5. Mirmomen S, Alavian SM, Hajarizadeh B, Ka- faee J, Yektaparast B, Zahedi MJ, et al. Epide- miology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med 2006; 9(4): 319-23.
  6. Sharifi-Mood B, Eshghi P, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi Med J 2007; 28(10): 1516-9.